CASE STUDY

High-Velocity Execution of a <$5M Phase 1 Oncology Study in the USA

Where Speed Meets Cost Efficiency—REV Clinical Delivers

Study Details

- Phase: Phase 1/2 Study
- Indication: Solid Tumor
- Patients: 28 (Phase 1a – Dose Escalation)
- Dose levels: 7 Doses
- Study Design: 3+3 design
- No of Sites: 6 sites
- Country of Execution: USA

The Challenge

Sponsor initiated a U.S. Phase 1 oncology study with limited seed funding and required rapid generation of initial safety data within a constrained budget to support the next financing round, while seeking a lean, agile partner capable of delivering cost-efficient, high-impact clinical execution solutions.

Strategic Approach & Execution

- Balanced Site Mix: Deployed an optimal blend of community and academic oncology centers to maximize reach and quality.
- High-Performing Community Sites: Prioritized Phase 1–experienced community centers to drive faster enrollment and operational efficiency.
- Smart Enrollment Design: Implemented efficient slot allocation and SEC planning to accelerate recruitment while maintaining healthy site competitiveness.
- Cost-Optimized Digital Stack: Leveraged a fit-for-purpose, cost-efficient clinical technology ecosystem (EDC, eTMF, CTMS) to deliver compliance without enterprise-level cost burden.
- Global Delivery Advantage: India-based backend execution driving cost efficiency without compromising quality or speed.

Outcome & Impact

- <100 Days to FPFV
- 40–60% Faster Startup
- 7 Cohorts Enrolled in 12 Months
- Delivered in $4.8M in the U.S.